Move to topTop
April 06, 2017

Ann Arbor, Mich. - April 6, 2017 - Terumo Cardiovascular (CV) Group today announced that Robert (Rob) DeRyke has been appointed President and CEO of Terumo CV Group, effective April 1, 2017, following the retirement of long-time President and CEO Mark Sutter. In this position, DeRyke will lead Terumo's global business related to the cardiopulmonary bypass market including Terumo Cardiovascular Systems (CVS), CV Group's operating company in the Unites States.

Prior to this appointment, DeRyke served as President of Terumo CV Group's Electromechanical (EM) Systems Division. "Under his leadership, Rob brought stability and improved profitability to the business," said Shinjiro Sato, President and CEO of Terumo Corporation, Terumo CV Group's parent company.

DeRyke takes lead of a company with deep expertise in the cardiac arena, well positioned for the future.

"We have a strong foundation of talent, technologies, and systems to build on as we deliver long-term value to our customers and their patients," said DeRyke.

Terumo CV Group is building momentum that will create a positive impact for healthcare providers and the critically ill patients they serve. Having recently cleared the shipping restrictions imposed as a condition of its 2011 consent decree, the company is preparing to return its flagship Terumo® Advanced Perfusion System 1 heart-lung machine to market in June 2017. As a market leader in oxygenators and cardiac monitoring technologies, Terumo CV Group will introduce its newest CAPIOX® oxygenator and CDI® inline blood gas monitoring system later this year, reinforcing the company's commitment to the global cardiac community.

DeRyke joined Terumo in 2012 as Vice President of Corporate Quality for Terumo CVS. He has over 25 years' experience in medical devices and pharmaceuticals, and has held executive leadership positions for Baxter Healthcare, Hospira, and Thermo-Fisher Scientific. He holds a Master of Business Administration from Michigan State University and a Bachelor of Science in Chemistry from Western Michigan University.

About Terumo Cardiovascular Group

Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information,

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.